The primary objective of the study is:
To evaluate the effect of the addition of navitoclax to ruxolitinib on spleen volume
The secondary objectives of the study are:
To assess the effect of the addition of navitoclax to ruxolitinib on total symptom score (TSS) as assessed by the Myelofibrosis Symptom Assessment Form (MFSAF) version 4.0 diary
To evaluate the effect of the addition of navitoclax to ruxolitinib on bone marrow fibrosis
To determine the overall response rate (ORR = sum of rates of complete remission [CR] +
partial remission [PR]) associated with the addition of navitoclax to ruxolitinib
To determine the rate of anemia response associated with the addition of navitoclax to
ruxolitinib
To describe the safety profile and PK profile observed with the addition of navitoclax to
ruxolitinib
Ruben Mesa